Mode
Text Size
Log in / Sign up
N/A Completed N=179

Follow-up Study to Evaluate Sustained Clearance Rates of Actinic Keratoses up to One Year

Actinic Keratoses
Source: ClinicalTrials.gov NCT00668733 ↗
Enrolled (actual)
179
Serious AEs
0.0%
Results posted
Jul 2010
Primary outcomePrimary: Number of Participants With Recurrence of AK Lesions — 52; 41 participants

Summary

The objective of this study was to obtain long-term sustained clearance rates for subjects previously treated with imiquimod creams in studies GW01-0702, GW01-0703, GW01-0704 and GW01-0705.

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Recurrence of AK Lesions
52; 41 —

Eligibility Criteria

Inclusion Criteria

  • Are willing and able to give informed consent;
  • Have successfully completed one of the following studies: GW01-0702, GW01- 0703, GW01-0704, or GW01-0705 and have been determined to be completely clear of AK lesions at the EOS visit in the designated treatment area from the previous study
  • Are willing to participate in the study as an outpatient, make visits to the study center for follow-up evaluation, and agree to comply with all study requirements.

Exclusion Criteria

  • None. All subjects who meet the inclusion criteria above may participate.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00668733). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search